Allspring Global Investments
APGE

Allspring Global Investments’s Apogee Therapeutics APGE Stock Holding History

Allspring Global Investments’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,052
Closed -$510K – 1879
2026
Q1 		$510K Buy
6,052
+617
+11% +$44.8K ﹤0.01% 1385
2025
Q4 		$412K Buy
+5,435
New +$342K ﹤0.01% 1428
2025
Q3 		– Sell
-4,931
Closed -$218K – 1631
2025
Q2 		$218K Buy
+4,931
New +$188K ﹤0.01% 1532
2024
Q4 		– Sell
-3,378
Closed -$198K – 1786
2024
Q3 		$198K Sell
3,378
-251
-7% -$12K ﹤0.01% 1673
2024
Q2 		$143K Buy
+3,629
New +$176K ﹤0.01% 1782

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Allspring Global Investments's APGE Position: Q2 2026 in Review

Allspring Global Investments sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 6,052 shares — an estimated $510K sold.

Allspring Global Investments first reported a position in APGE in Q2 2024 and held it in 5 quarters. The position peaked at $510K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Allspring Global Investments reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Allspring Global Investments sold 6,052 Apogee Therapeutics shares in Q2 2026, an estimated $510K.
  • Allspring Global Investments first reported a position in Apogee Therapeutics in Q2 2024 and held it in 5 quarters.
  • Allspring Global Investments's Apogee Therapeutics position peaked at $510K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.